Literature DB >> 87082

Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis.

C E Orfanos, G K Steigleder, H Pullmann, P H Bloch.   

Abstract

The combined application of an oral retinoid (Ro 10-9359) and phototherapy with predominantly UVB radiation (Selective Ultraviolet Phototherapy=SUP) is a new, highly effective method of treating psoriasis. It has few side effects and can be performed on an out-patient basis. With the aid of this combined treatment we achieved good or very good improvement in 19 out of 23 patients with generalized psoriasis (=82.6%). The average number of radiation sessions required to achieve this was 22.9, and the mean total therapeutic dose (TTD) was 73 J/cm2. In a control group of 40 psoriasis patients, who received only radiation therapy, we achieved good or very good results in only 60% with an average of 26 radiation sessions and 94 J/cm2 TTD. The effect of the oral retinoid and UVB radiation therapy is apparently additive, since the retinoid does not increase the sensitivity of the skin to light.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87082

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  13 in total

Review 1.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Giao Do; Camille Hua; Canelle Mazaud; Catherine Droitcourt; Carolyn Hughes; John R Ingram; Luigi Naldi; Olivier Chosidow; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2017-12-22

Review 2.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

3.  Retinoids. Therapeutic use in dermatology.

Authors:  G L Peck
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 4.  Psoriasis. A review of recent advances in treatment.

Authors:  E M Farber; L Nall
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

5.  Immunological features of psoriasis. Effects of Ro-109359, concanavalin A, pokeweed mitogen, and methotrexate on cultivated lymphocytes.

Authors:  A A Bialasiewicz; D Lubach; S Marghescu
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 6.  Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

7.  The antipsoriatic drug metabolite etretin (Ro 10-1670) alters the metabolism of fatty acids in human keratinocytes in culture.

Authors:  K Punnonen; T Puustinen; C T Jansén
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

Review 8.  Clinical pharmacokinetics of the retinoids.

Authors:  R W Lucek; W A Colburn
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

9.  [Beneficial effect of oral retinoid in psoriatic hyperproliferation. Autoradiographic studies on involved and non involved skin (author's transl)].

Authors:  E Dierlich; C E Orfanos; H Pullmann; G K Steigleder
Journal:  Arch Dermatol Res       Date:  1979-03-31       Impact factor: 3.017

10.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Liz Doney; Corinna Dressler; Camille Hua; Carolyn Hughes; Luigi Naldi; Sivem Afach; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.